HELP Helus Pharma

$11.99

Helus Pharma (HELP) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $0.80 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.8% since its last earnings release on August 14, 2026.

Helus Pharma Missed Consensus Estimates
Friday, August 14, 2026 · 7:28 AM ET
Earnings Date
2nd Quarter, Sep 2026
Nov 13
Friday · 7:30 AM ET
Earnings Whisper
-
vs ($0.80)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP -

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Helus Pharma

Helus Pharma is a clinical stage pharmaceutical company. Its lead candidate includes HLP003 and HLP004. Helus Pharma, formerly known as Cybin Inc., is based in BOSTON.

Sector

Healthcare

Industry

Drug Manufacturers/Other